GlassScriptPhysician profile
Christopher Morrison Peterson
NPI 1609891472
$1,396.87
in general payments reported to CMS, 2019-2025
18 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $152 · 2021: $148 · 2022: $33.59 · 2023: $395 · 2024: $365 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473 · Education: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.15 |
| Education | $388.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $610.04 | 2020-2025 | Tremfya |
| Genentech USA, INC. | $117.18 | 2019-2024 | Erivedge |
| E.R. Squibb & Sons, L.L.C. | $115.07 | 2023-2024 | Sotyktu |
| Abbvie INC. | $97.09 | 2019-2024 | |
| Incyte Corporation | $73.99 | 2021-2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $54.51 | 2019-2021 | |
| Pfizer INC. | $44.18 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $43.61 | 2023-2024 | Odomzo, Blu-U |
| Arcutis Biotherapeutics, INC. | $42.60 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $38.89 | 2021-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.31 | 2019-2021 | |
| Lilly USA, LLC | $23.20 | 2023 | Olumiant, Taltz |
| Amgen INC. | $20.70 | 2021 | |
| Dusa Pharmaceuticals, INC. | $17.06 | 2019 | |
| Genzyme Corporation | $16.66 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $15.47 | 2024 | Adbry |
| Prugen, INC. Pharmaceuticals | $14.71 | 2019 | |
| Genentech, INC. | $14.60 | 2023 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.